2019
Characteristics of High Cardiovascular Risk in 1.7 Million Chinese Adults.
Lu J, Lu Y, Yang H, Bilige W, Li Y, Schulz W, Masoudi FA, Krumholz HM. Characteristics of High Cardiovascular Risk in 1.7 Million Chinese Adults. Annals Of Internal Medicine 2019, 170: 298-308. PMID: 30776800, DOI: 10.7326/m18-1932.Peer-Reviewed Original ResearchConceptsHigh CVD riskCVD riskHigh riskHigh cardiovascular disease riskCardiovascular risk increasesHigh cardiovascular riskOverall study populationCardiovascular disease riskBody mass indexMultivariable mixed modelsNational Health CommissionAntihypertensive medicationsAspirin useCardiovascular riskCVD screeningMass indexStudy populationChinese adultsHan ethnicityDisease riskStatinsMixed modelsHealth CommissionSocioeconomic statusPopulation subgroups
2017
Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis
Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis. JACC Cardiovascular Imaging 2017, 10: 938-952. PMID: 28797417, DOI: 10.1016/j.jcmg.2017.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmerican Heart AssociationBayes TheoremClinical Decision-MakingComputer SimulationCoronary AngiographyCoronary Artery DiseaseCoronary VesselsCost-Benefit AnalysisDecision Support TechniquesDrug CostsFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedModels, EconomicMonte Carlo MethodMultivariate AnalysisPractice Guidelines as TopicPredictive Value of TestsQuality of LifeQuality-Adjusted Life YearsTime FactorsTreatment OutcomeUnited StatesVascular CalcificationConceptsCoronary artery calciumQuality-adjusted life yearsStatin therapyArtery calciumLong-term statin therapyAtherosclerotic cardiovascular disease eventsCholesterol management guidelinesIncremental cost-effectiveness ratioCardiovascular disease eventsAtherosclerotic cardiovascular diseaseCost-effectiveness ratioCost-effectiveness analysisStatin candidatesCholesterol managementCardiovascular diseaseTreatment decisionsAmerican CollegeDisease eventsLifetime horizonLife yearsAmerican HeartSocietal perspectiveManagement guidelinesStatinsPatients
2016
National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011
Zhang L, Li J, Li X, Nasir K, Zhang H, Wu Y, Hu S, Wang Q, Downing NS, Desai NR, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, . National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011. PLOS ONE 2016, 11: e0150806. PMID: 27058862, PMCID: PMC4825974, DOI: 10.1371/journal.pone.0150806.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIntensive statin therapyLow-density lipoprotein cholesterolAcute myocardial infarction patientsStatin therapyMyocardial infarction patientsMyocardial infarctionStatin useLipoprotein cholesterolInfarction patientsHalf of patientsLong-term mortalityUse of statinsHospitalized patientsIntensive therapyChinese patientsCardiovascular diseaseEffective treatmentPatientsInfarctionStatinsTherapyChinese hospitalsTreatment intensityCholesterol
2014
The Guidelines Battle on Starting Statins
D'Agostino RB, Ansell BJ, Mora S, Krumholz HM. The Guidelines Battle on Starting Statins. New England Journal Of Medicine 2014, 370: 1652-1658. PMID: 24758622, DOI: 10.1056/nejmclde1314766.Peer-Reviewed Original Research
2013
When Choosing Statin Therapy: The Case for Generics
Green JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When Choosing Statin Therapy: The Case for Generics. JAMA Internal Medicine 2013, 173: 229-232. PMID: 23303273, DOI: 10.1001/jamainternmed.2013.1529.Commentaries, Editorials and Letters
2011
Use of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrials
2006
Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure
Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure. Circulation 2006, 113: 1086-1092. PMID: 16490817, DOI: 10.1161/circulationaha.105.591446.Peer-Reviewed Original ResearchConceptsHeart failureStatin therapyElderly patientsOlder patientsCoronary artery disease statusCox proportional hazards modelCurrent HF therapiesLong-term mortalityPrimary discharge diagnosisGroup of patientsTotal cholesterol levelsRandomized clinical trialsEligible Medicare beneficiariesProportional hazards modelYears of ageHF therapyStatin useClinical characteristicsDischarge diagnosisCholesterol levelsHospital characteristicsClinical trialsPhysician specialtyTeaching hospitalStatinsHydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction
Foody JM, Rathore SS, Galusha D, Masoudi FA, Havranek EP, Radford MJ, Krumholz HM. Hydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction. Journal Of The American Geriatrics Society 2006, 54: 421-430. PMID: 16551308, PMCID: PMC2797316, DOI: 10.1111/j.1532-5415.2005.00635.x.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAged, 80 and overAtorvastatinCholesterol, LDLDrug PrescriptionsFatty Acids, MonounsaturatedFemaleFluvastatinFollow-Up StudiesHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesLovastatinMaleMyocardial InfarctionOdds RatioPravastatinPyridinesPyrrolesRetrospective StudiesSurvival RateTreatment OutcomeConceptsAcute myocardial infarctionHydroxymethylglutaryl-CoA reductase inhibitorsStatin therapyMyocardial infarctionLower mortalityOlder personsReductase inhibitorsPrincipal discharge diagnosisAcute care hospitalsCause mortalityEligible patientsOlder patientsYounger patientsCare hospitalDischarge prescriptionsPrimary outcomeDischarge diagnosisHospital characteristicsEfficacy dataMedicare patientsMultivariable modelObservational studyPatientsStatinsDischarge statins
2003
Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint
Foody JM, Krumholz HM. Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint. The American Journal Of Geriatric Cardiology 2003, 12: 357-360. PMID: 14610384, DOI: 10.1111/j.1076-7460.2003.02912.x.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePrimary preventionArtery diseaseOvert coronary artery diseaseRisk of myositisCardiovascular disease eventsRole of statinsUse of statinsAge 65 yearsBalance of risksCardiovascular eventsStatin therapyPatient preferencesCholesterol levelsCardiovascular diseaseOctogenariansClinical uncertaintyDisease eventsCurrent evidenceStatinsAge groupsDiseasePreventionRiskMyositis